Shareholder battle affects ISG results

Article

Uncertainty over the outcome of a shareholder proxy battle hindered1997 second-quarter revenues for medical imaging software developerISG Technologies. The Mississauga, Ontario, firm reported lastweek that revenues dropped 11% in the period

Uncertainty over the outcome of a shareholder proxy battle hindered1997 second-quarter revenues for medical imaging software developerISG Technologies. The Mississauga, Ontario, firm reported lastweek that revenues dropped 11% in the period (end-December).

ISG in December fended off a bid for control of the company launchedby Quorum Growth, a dissident shareholder group (SCAN 1/8/97).Quorum proposed to bring back former president and CEO ThomasCafarella, divest the company's image-guided surgery business,and refocus the firm on PACS software development.

While ISG won the battle, the turmoil resulted in a slowdown inthe company's sales, particularly in the image-guided surgerybusiness that Quorum said it would sell, according to chairmanand CEO Dr. Michael Greenberg.

For the quarter, ISG's revenues were $6.3 million (Canadian),down from $7.2 million in the second quarter of 1996. The firmhad a loss of $1.8 million (which included a $1.5 million one-timecharge), compared with an $88,000 profit in the second quarterof 1996. The one-time charge included costs for the proxy battleand for writing off inventory for ISG's Pulsus product line.

In announcing the results, Greenberg said that ISG's revenue growthresumed once the proxy battle was over, and the company expectsto post improved results in its third and fourth quarters.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.